Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

• Source: Shutterstock

San Mateo, CA-based Route 92 Medical will accelerate global commercialization of its neurovascular intervention portfolio and pursue regulatory authorizations in new geographies with a $50m extension to its Series F financing round announced in November 2023.

The extension – compliments of returning investors US Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group, as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business